» Articles » PMID: 2580831

Modulation of Apolipoprotein B Antigenic Determinants in Human Low Density Lipoprotein Subclasses

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1985 Apr 25
PMID 2580831
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

To investigate the effect of low density lipoprotein (LDL) heterogeneity on the conformation of LDL apolipoprotein B (apo-B), the immunoreactivities of 6 monoclonal antibodies against LDL apo-B were measured in 3 LDL subfractions isolated by equilibrium density gradient ultracentrifugation. To ensure a broad range of LDL particles, the LDL subfractions were prepared from normal subjects and patients with hyperapobetalipoproteinemia. With 3 of the antibodies, 1D1, 5E11, and 3A10, LDL fractions 1 (the most buoyant), 2 (the intermediate), and 3 (the densest) were equally immunoreactive and competed similarly with reference whole LDL. In contrast, with 3 other antibodies, 2D8, 3F5, and 4G3, fraction 1 was significantly more reactive than fraction 3; that is for each in turn, 290, 250, and 150% more of the densest LDL protein was required to achieve the same displacement as with fraction 1. Further, the immunoreactivities of the 3 LDL fractions with antibodies 2D8, 3F5, and 4G3 were negatively correlated with their LDL cholesterol to LDL protein ratio with r values of 0.727, 0.898, and 0.870, respectively, suggesting that as LDL particle size decreases, the conformation of the LDL apo-B changes progressively. It is of interest that the antigenic determinants recognized by 3F5 and 4G3 are close to the LDL receptor recognition site on LDL apo-B. Therefore, it is possible that the reduced immunoreactivity of these determinants in dense LDL may be the in vitro correlate of the reduced fractional catabolics rate of dense LDL compared to buoyant LDL previously observed in vivo.

Citing Articles

Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk.

Glavinovic T, Thanassoulis G, de Graaf J, Couture P, Hegele R, Sniderman A J Am Heart Assoc. 2022; 11(20):e025858.

PMID: 36216435 PMC: 9673669. DOI: 10.1161/JAHA.122.025858.


Molecular structure of low density lipoprotein: current status and future challenges.

Prassl R, Laggner P Eur Biophys J. 2008; 38(2):145-58.

PMID: 18797861 DOI: 10.1007/s00249-008-0368-y.


Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome.

Kwon S, Yoon S, Kang T, Kwon H, Kim J, Rhee J Yonsei Med J. 2006; 47(3):405-14.

PMID: 16807992 PMC: 2688162. DOI: 10.3349/ymj.2006.47.3.405.


Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.

Sniderman A, Bergeron J, Frohlich J CMAJ. 2001; 164(1):44-7.

PMID: 11209748 PMC: 80634.


Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel....

Berglund L, Witztum J, Galeano N, Khouw A, Ginsberg H, Ramakrishnan R J Lipid Res. 1998; 39(4):913-24.

PMID: 9555954 PMC: 3988111.